首頁 > 市場調查報告書 > 製藥

市場調查報告書

商品編碼

1481298

皮質類固醇市場規模 - 按產品（糖皮質激素、鹽皮質激素）、給藥途徑（局部、注射、口服、吸入）、應用（皮膚過敏、風濕病適應症）、配銷通路和預測，2024 - 2032

Corticosteroids Market Size - By Product (Glucocorticoids, Mineralocorticoids), Route of Administration (Topical, Injectable, Oral, Inhaled), Application (Skin Allergies, Rheumatology Indications), Distribution Channel & Forecast, 2024 - 2032

出版日期: 2024年03月01日 | 出版商:

Global Market Insights Inc. | 英文 120 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

由於氣喘、類風濕性關節炎和發炎性腸道疾病等慢性疾病的盛行率不斷增加，預計 2024 年至 2032 年全球皮質類固醇市場規模的複合年成長率將達到 7.5%。皮質類固醇因其抗發炎和免疫抑制特性而被廣泛使用，這使得它們在這些疾病的治療中不可或缺。此外，老年人口的不斷成長，加上生活方式的改變和環境因素，進一步導致皮質類固醇治療的需求增加。根據世界衛生組織的統計，到2050年，60歲以上人口的比例將達到22%。

皮質類固醇市場根據產品、給藥途徑、應用、配銷通路和地區進行分類。

以產品來看，鹽皮質激素產品領域的產業規模到 2032 年可能會創下 6.8% 的複合年成長率，因為它在調節體內電解質平衡和體液量方面發揮關鍵作用。鹽皮質激素，例如醛固酮，在維持血壓和鈉鉀平衡方面發揮著至關重要的作用，這使得它們在治療艾迪生氏病和先天性腎上腺增生等疾病中不可或缺。隨著腎上腺功能不全及相關疾病的日益流行，預計未來幾年對鹽皮質激素的需求將激增。

在應用方面，內分泌領域的皮質類固醇產業預計2024年至2032年的複合年成長率為7.6%。增生。這些合成荷爾蒙模仿皮質醇（人體的天然壓力荷爾蒙）的作用，有助於恢復荷爾蒙平衡和減輕與內分泌失調相關的症狀。隨著研究不斷揭示內分泌疾病的複雜性，基於皮質類固醇的療法的採用預計將穩步成長。

從地區來看，到2032 年，歐洲皮質類固醇市場規模將以7.4% 的複合年成長率成長，這歸因於完善的醫療基礎設施、高額醫療支出以及人們對皮質類固醇治療益處的認知不斷提高。此外，慢性呼吸道疾病和自體免疫疾病的盛行率不斷上升，需要使用皮質類固醇來進行有效的疾病管理。此外，主要市場參與者為擴大其在歐洲國家的業務而採取的策略性舉措進一步促進了市場成長。

產業生態系統分析
產業影響力
- 成長動力
  - 藥物配方的進步
  - 慢性病發生率增加
  - 研發投資激增
  - 癌症盛行率不斷上升
- 產業陷阱與挑戰
  - 與長期使用皮質類固醇相關的不良反應和副作用
  - 政府對企業的定價壓力
成長潛力分析
監管環境
技術景觀
波特的分析
PESTEL分析
未來市場趨勢

第 4 章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
競爭定位矩陣
戰略儀表板

第 5 章：市場估計與預測：按產品分類，2018 年 - 2032 年

主要趨勢
糖皮質激素
鹽皮質激素

第 6 章：市場估計與預測：按管理途徑，2018 年 - 2032 年

主要趨勢
專題
可注射
口服
吸入

第 7 章：市場估計與預測：按應用分類，2018 年 - 2032 年

主要趨勢
皮膚過敏
胃腸病學
內分泌科
急性呼吸道疾病
風濕病適應症
其他應用

第 8 章：市場估計與預測：按配銷通路，2018 年 - 2032 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第 9 章：市場估計與預測：按地區分類，2018 年 - 2032 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 義大利
- 西班牙
- 歐洲其他地區
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- 韓國
- 亞太地區其他地區
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 拉丁美洲其他地區
中東和非洲
- 沙烏地阿拉伯
- 南非
- 阿拉伯聯合大公國
- 中東和非洲其他地區

第 10 章：公司簡介

AbbVie Inc.
Astellas Pharma Inc.
AstraZeneca plc
Bausch Health Companies Inc.
Bayer AG
Cipla Limited
Eli Lilly and Company
GlaxoSmithKline plc
Lupin Limited
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
Sanofi S.A

簡介目錄

Product Code: 8378

Global corticosteroids market size is anticipated to witness 7.5% CAGR from 2024 to 2032, due to the increasing prevalence of chronic ailments, such as asthma, rheumatoid arthritis, and inflammatory bowel diseases. Corticosteroids are widely prescribed for their anti-inflammatory and immunosuppressive properties, making them indispensable in the management of these conditions. Moreover, the growing geriatric population, coupled with lifestyle changes and environmental factors are further contributing to the escalating demand for corticosteroid-based therapies. As per the WHO stats, the population of 60 years and older will reach 22% by 2050.

The corticosteroids market is classified based on product, route of administration, application, distribution channel, and region.

By product, the industry size from the mineralocorticoids product segment may record 6.8% CAGR till 2032 owing to its pivotal role in regulating electrolyte balance and fluid volume in the body. Mineralocorticoids, such as aldosterone play a crucial role in maintaining blood pressure and sodium-potassium balance, making them indispensable in the treatment of conditions like Addison's disease and congenital adrenal hyperplasia. With the increasing prevalence of adrenal insufficiency and related disorders, the demand for mineralocorticoids is projected to surge in the coming years.

In terms of application, the corticosteroids industry from the endocrinology segment is predicted to witness 7.6% CAGR from 2024 to 2032. Corticosteroids find widespread application in the management of hormonal disorders, including adrenal insufficiency, Cushing's syndrome, and congenital adrenal hyperplasia. These synthetic hormones mimic the action of cortisol, the body's natural stress hormone, and are instrumental in restoring hormonal balance and alleviating symptoms associated with endocrine disorders. As research continues to unravel the complexities of endocrine diseases, the adoption of corticosteroid-based therapies is expected to witness a steady rise.

Regionally, the Europe corticosteroids market size will expand at 7.4% CAGR through 2032, attributed to the presence of a well-established healthcare infrastructure, high healthcare expenditure, and increasing awareness regarding the benefits of corticosteroid therapy. Moreover, the rising prevalence of chronic respiratory diseases and autoimmune disorders is necessitating the use of corticosteroids for effective disease management. Additionally, strategic initiatives undertaken by key market players to expand their presence in European countries are further augmenting market growth.

Chapter 1 Methodology & Scope

1.1 Market scope & definition
1.2 Base estimates & calculations
1.3 Data collection
1.4 Forecast parameters
1.5 Data validation
1.6 Data sources
- 1.6.1 Primary
- 1.6.2 Secondary
  - 1.6.2.1 Paid sources
  - 1.6.2.2 Unpaid sources

Chapter 2 Executive Summary

2.1 Industry 360 degree synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Advancements in drug formulations
  - 3.2.1.2 Increasing incidence of chronic diseases
  - 3.2.1.3 Surging investment in research and development
  - 3.2.1.4 Growing prevalence of cancers
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Adverse reactions and side effects associated with prolonged use of Corticosteriods
  - 3.2.2.2 Pricing pressure on the companies by government
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Technological landscape
3.6 Porter's analysis
- 3.6.1 Supplier power
- 3.6.2 Buyer power
- 3.6.3 Threat of new entrants
- 3.6.4 Threat of substitutes
- 3.6.5 Industry rivalry
3.7 PESTEL analysis
3.8 Future market trends

Chapter 4 Competitive Landscape, 2023

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive positioning matrix
4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2018 - 2032 ($ Mn)

5.1 Key trends
5.2 Glucocorticoids
5.3 Mineralocorticoids

Chapter 6 Market Estimates and Forecast, By Route of Administration, 2018 - 2032 ($ Mn)

6.1 Key trends
6.2 Topical
6.3 Injectable
6.4 Oral
6.5 Inhaled

Chapter 7 Market Estimates and Forecast, By Application, 2018 - 2032 ($ Mn)

7.1 Key trends
7.2 Skin allergies
7.3 Gastroenterology
7.4 Endocrinology
7.5 Acute respiratory diseases
7.6 Rheumatology indications
7.7 Other applications

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2018 - 2032 ($ Mn)

8.1 Key trends
8.2 Hospital pharmacies
8.3 Retail pharmacies
8.4 Online pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2018 - 2032 ($ Mn)

9.1 Key trends
9.2 North America
- 9.2.1 U.S.
- 9.2.2 Canada
9.3 Europe
- 9.3.1 Germany
- 9.3.2 UK
- 9.3.3 France
- 9.3.4 Italy
- 9.3.5 Spain
- 9.3.6 Rest of Europe
9.4 Asia Pacific
- 9.4.1 China
- 9.4.2 Japan
- 9.4.3 India
- 9.4.4 Australia
- 9.4.5 South Korea
- 9.4.6 Rest of Asia Pacific
9.5 Latin America
- 9.5.1 Brazil
- 9.5.2 Mexico
- 9.5.3 Argentina
- 9.5.4 Rest of Latin America
9.6 Middle East and Africa
- 9.6.1 Saudi Arabia
- 9.6.2 South Africa
- 9.6.3 UAE
- 9.6.4 Rest of Middle East and Africa